Response to Letter Regarding Article, “Greater Clinical Benefit of More Intensive Oral Antiplatelet Therapy With Prasugrel in Patients With Diabetes Mellitus in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel: Thrombolysis in Myocardial Infarction 38”-Reference-Cited by-同舟云学术

Response to Letter Regarding Article, “Greater Clinical Benefit of More Intensive Oral Antiplatelet Therapy With Prasugrel in Patients With Diabetes Mellitus in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel: Thrombolysis in Myocardial Infarction 38”

Published:2009-06-30 Issue:25 Volume:119 Page:
ISSN:0009-7322
Container-title:Circulation
language:en
Short-container-title:Circulation

Author:

Wiviott Stephen D.¹,Braunwald Eugene¹,Murphy Sabina A.¹,McCabe Carolyn H.¹,Antman Elliott M.¹,Angiolillo Dominick J.²,Meisel Simha³,Dalby Anthony J.⁴,Verheugt Freek W.A.⁵,Goodman Shaun G.⁶,Corbalan Ramon⁷,Purdy Drew A.⁸

Affiliation:

1. TIMI Study Group, Cardiovascular Division, Department of Medicine, Harvard Medical School, Brigham and Women’s Hospital, Boston, Mass

2. University of Florida College of Medicine, Jacksonville, Fla

3. Hillel Yaffe Medical Center, Hadera, Israel

4. Millpark Hospital, Johannesburg, South Africa

5. Department of Cardiology, University Hospital Nijmegen, Nijmegen, the Netherlands

6. Canadian Heart Research Center, University of Toronto, St. Michael’s Hospital, Toronto, Ontario, Canada

7. Department of Cardiology, Catholic University School of Medicine, Santiago, Chile

8. Black Hills Cardiovascular Research Group, Black Hills, SD

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Physiology (medical),Cardiology and Cardiovascular Medicine

Link

https://www.ahajournals.org/doi/pdf/10.1161/CIRCULATIONAHA.108.844050

Reference5 articles.

1. Greater Clinical Benefit of More Intensive Oral Antiplatelet Therapy With Prasugrel in Patients With Diabetes Mellitus in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis in Myocardial Infarction 38

2. Antiplatelet therapy in type 2 diabetes mellitus

3. Will Diabetes Save the Platelet Blockers?

4. Early and Late Benefits of Prasugrel in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention